KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Divestments (2018 - 2025)

Historic Divestments for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to $20.6 million.

  • Takeda Pharmaceutical's Divestments rose 14809.93% to $20.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $297.3 million, marking a year-over-year increase of 5203.92%. This contributed to the annual value of $134.9 million for FY2025, which is 249.36% down from last year.
  • According to the latest figures from Q4 2025, Takeda Pharmaceutical's Divestments is $20.6 million, which was up 14809.93% from $2.4 million recorded in Q3 2025.
  • Over the past 5 years, Takeda Pharmaceutical's Divestments peaked at $3.8 billion during Q1 2021, and registered a low of -$48471.0 during Q3 2023.
  • Its 5-year average for Divestments is $351.5 million, with a median of $20.6 million in 2025.
  • As far as peak fluctuations go, Takeda Pharmaceutical's Divestments tumbled by 9414.59% in 2022, and later surged by 7463654.33% in 2024.
  • Over the past 5 years, Takeda Pharmaceutical's Divestments (Quarter) stood at $19.5 million in 2021, then surged by 1048.07% to $224.2 million in 2022, then plummeted by 100.02% to -$48471.0 in 2023, then soared by 17198.88% to $8.3 million in 2024, then soared by 148.1% to $20.6 million in 2025.
  • Its last three reported values are $20.6 million in Q4 2025, $2.4 million for Q3 2025, and $202.4 million during Q2 2025.